Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C
https://doi.org/10.22625/2072-6732-2019-11-4-65-71
Abstract
Objective: to analyze the efficacy and safety of using direct antiviral action drug narlaprevir/ritonavir in combination with the prolonged alpha-interferon and ribavirin drugs in the conditions of day-time hospitals of St. Petersburg and. Novgorod.
Materials and methods: The study included. 35 patients with CHC of the 1st genotype. For treating these patients, a three-component regimen was used, which included the use of narlaprevir/ritonavir in combination, with peg-interferon and ribavirin.
Results: among all patients included, in the study, a sustained, virological response was noted, in 85,7%. Early virological response was observed, in 91,3% cases. The recurrence rate was observed, in 10% patients. In 3 patients, therapy was interrupted, for the following reasons: due to inefficiency, the development of serious adverse events, and on its own initiative.
Conclusion: the data obtained, demonstrate high, virological and. clinical efficacy and. safety of narlaprevir in combination with peg-interferon and ribavirin, in the treatment of chronic viral hepatitis C.
About the Authors
V. V. Basina
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
S. E. Kalach
Novgorod regional infectious diseases hospital
Russian Federation
Competing Interests: not
Russian Federation
Velikiy Novgorod
Competing Interests: not
N. V. Tyurenkova
Clinical Infectious hospital named after S.P. Botkin
Russian Federation
Competing Interests: not
Russian Federation
Saint-Petersburg
Competing Interests: not
M. E. Semenova
Clinical Infectious hospital named after S.P. Botkin
Russian Federation
Competing Interests: not
Russian Federation
Saint-Petersburg
Competing Interests: not
E. Yu. Yushina
Clinical Infectious hospital named after S.P. Botkin
Russian Federation
Competing Interests: not
Russian Federation
Saint-Petersburg
Competing Interests: not
E. G. Gordievskaya
Children's Infectious Diseases Hospital № 3
Russian Federation
Competing Interests: not
Russian Federation
Saint-Petersburg
Competing Interests: not
R. A. Ganchenko
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
Е. V. Esaulenko
Saint-Petersburg State Pediatric Medical University; Clinical Infectious hospital named after S.P. Botkin
Russian Federation
Competing Interests: not
Russian Federation
Saint-Petersburg
Competing Interests: not
References
1. O sostoyanii sanitarno-epidemiologicheskogo blago-poluchiya naseleniya v Rossiyskoy Federatsii v 2017 godu // Gosudarstvennyy doklad. Moskva. Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka. 2018. S. 268.
2. Global hepatitis report, 2017 // World Health Organization. P. 1-61
3. Sukhoruk, A.A. Tsirroz pecheni kak iskhod khronichesk-ogo gepatita S. / A. A. Sukhoruk, O.A. Gerasimova, E. V. Esau-lenko// Zhurnal infektologii. — 2014. — T. 6. № 1. — S. 67-71.
4. Novak K.E. Postmortal'naya morfologicheskaya khara-kteristika pecheni bol'nykh khronicheskimi virusnymi gepa-titami s klinicheskimi priznakami tsirroza. / K. E. Novak, V.E. Karev, N.V. Dunaeva, E.V. Esaulenko. //Rossiyskiy meditsinskiy zhurnal. - 2011. -№ 2. -S. 8-11.
5. Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka [Elektronnyy resurs] // Rospotrebnadzor — Rezhim dostupa: http://rospotreb-nadzor.ru/activities/statisticalmaterials/statictic_details.php?ELEMENT_ID=7804
6. Esaulenko E.V. Khronicheskiy virusnyy gepatit s v Seve-ro-Zapadnom federal'nom okruge. / E. V. Esaulenko, A.A. Suk-horuk, M.V. Ponyatishina., R.A. Ganchenko // Zhurnal VICh-infektsiya i immunosupressii. — 2017. —T. 9. № 2. — S. 74-81.
7. EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatologi. 2015; 63:199-236.
8. Virusnye gepatity v rossiyskoy federatsii: analiticheskiy obzor, 2016, Ministerstvo zdravookhraneniya i sotsial'nogo raz-vitiya Rossiyskoy Federatsii, Federal'noe agentstvo po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, Federal'noe gos. uchrezhdenie Sankt-Peterburgskiy nauchno-issledovatel'skiy institut epidemiologii i mikrobiologii im. Pas-tera. — SPb.: NIIEM im. Pastera, 2016. — 132 s.
9. Esaulenko E. V. Otechestvennyy ingibitor proteazy Nar-laprevir dlya terapii khronicheskogo gepatita S 1 genotipa vi-rusa / E.V. Esaulenko //Zhurnal Infektologii. — 2015. —T.7. — № 53. — S. 99-100.
10. Maevskaya M.V. Effektivnost' i bezopasnost' otechest-vennogo ingibitora proteazy Narlaprevira u pervichnykh i ranee lechennykh patsientov s khronicheskim gepatitom S, vyz-vannym virusom 1-go genotipa, bez tsirroza pecheni (rezul'taty issledovaniya PIONER)/ M. V. Maevskaya, V.T. Ivashkin, E.V. Esaulenko i dr // Rossiyskiy zhurnal gatroenterologii, gepatologii,koloproktologii. — 2017. — T.27. — №6. — S. 41-51.
11. Gusev D.A., Effektivnost' zatrat na Narlaprevir pri ter-apii khronicheskogo gepatita S (1 genotip) u patsientov, ne poluchavshikh ranee protivovirusnye preparaty i pri retsidive zabolevaniya/ D. A. Gusev, A.V. Rudakova, A. N. Uskov, L.N. Konovalova, Yu.V. Lobzin. //Zhurnal Infektologii. —2016. — T.8. — № 3. — S. 122-125.
12. Nikolaeva L.I., Virus gepatita S: misheni dlya tera-pii i novye lekartsvennye preparaty/ L. I. Nikolaeva, G. V. Sapronov // Zhurnal virusologii. — 2012. — №5. — S. 10-15.
13. Idrees S., Ashfaq UA. Инфекция HCV и ингибиторы сериновой протеиназы NS-3 // J. Virol Mycol. 2013. Vol. 2. P. 112. DOI: 10, 4172/2161-0517.1000112.
14. Ghany, M. G, Strader D.B, Thomas D. L. Diagnosis, management, and treatment of hepatitis C: an update // J. Hepatology. 2009. Vol.49. P.1335— 1374.
15. Jacobson I. M, McHutchison J. G, Dusheiko G. Telapre-vir for previously untreated chronic hepatitis C virus infection // J. Med. 2011. Vol. 364. P. 2405 — 2416.
16. Poordad, F, McCone J, Bacon B.R. Boceprevir for untreated chronic HCV genotype 1 infection // J. Med. 2011. Vol.364. P.1195-1206.
17. Zeuzem S. Chronic hepatitis C: Standard treatment and remaining challenges // J. Internist. 2018. Vol. 59(6). P. 528535. DOI: 10.1007/s00108-018-0429-y.
18. Esaulenko E.V., Nikitina O.E. Obosnovanie neobkhodi-mosti troynoy terapii khronicheskogo gepatita S. / E.V. Esau-lenko, O.E. Nikitina //Zhurnal Infektsionnye bolezni. — 2013. — T. 11. —№ 2. — S. 69-73.
19. Esaulenko E.V. Klinicheskiy opyt bezinterferonovoy terapii khronicheskogo gepatita S posle transplantatsii pecheni / E.V. Esaulenko, A.A. Sukhoruk, V.B. Musatov i dr. // Zhurnal Infektsionnye bolezni. —2013. —T. 16. — № 3. — S. 79-86.
20. Wang H, Geng L, Chen BZ, Ji M. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M + R155K, T54A, and A156T mutations of HCV NS3/4A protease // J. Biochem Cell Biol. 2014 Oct;92 (5):357-69. DOI: 10.1139/bcb-2014-0039. Epub 2014 Jul 23.
21. Shunmugam L., Ramharack P., Soliman MES. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors // J. Protein. 2017 Oct; 36(5):397-406. DOI: 10.1007/s10930-017-9736-8
22. Isakov V., Koloda D., Tikhonova N., Kikalishvili T., etc. Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis // J. Antimi-crob Agents Chemother. 2016 Nov 21; 60(12):7098-7104. DOI: 10.1128/AAC.01044-16 Print 2016 Dec.
Review
For citations:
Basina V.V., Kalach S.E., Tyurenkova N.V., Semenova M.E., Yushina E.Yu., Gordievskaya E.G., Ganchenko R.A., Esaulenko Е.V. Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C. Journal Infectology. 2019;11(4):65-71. (In Russ.) https://doi.org/10.22625/2072-6732-2019-11-4-65-71
Views:
849
.png)
.png)
Email this article 